Ichiro Kawada

2.1k total citations
56 papers, 1.1k citations indexed

About

Ichiro Kawada is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ichiro Kawada has authored 56 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Ichiro Kawada's work include Lung Cancer Treatments and Mutations (27 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ichiro Kawada is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ichiro Kawada collaborates with scholars based in Japan, United States and France. Ichiro Kawada's co-authors include Kenzo Soejima, Katsuhiko Naoki, Hiroyuki Yasuda, Tomoko Betsuyaku, Junko Hamamoto, Shigenari Nukaga, Keita Masuzawa, Ichiro Nakachi, Shinnosuke Ikemura and Toshiyuki Hirano and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Ichiro Kawada

55 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ichiro Kawada Japan 18 673 576 516 180 97 56 1.1k
Erina Hatashita Japan 15 492 0.7× 579 1.0× 588 1.1× 130 0.7× 126 1.3× 17 1.0k
Ken Uchibori Japan 15 614 0.9× 567 1.0× 360 0.7× 156 0.9× 64 0.7× 59 885
Junko Hamamoto Japan 16 535 0.8× 446 0.8× 408 0.8× 153 0.8× 61 0.6× 27 808
Francesca Casaluce Italy 15 462 0.7× 512 0.9× 326 0.6× 140 0.8× 56 0.6× 38 841
Atsuko Ogino Japan 10 673 1.0× 527 0.9× 498 1.0× 176 1.0× 131 1.4× 18 917
Paola Bordi Italy 17 798 1.2× 800 1.4× 413 0.8× 353 2.0× 90 0.9× 51 1.2k
Sachdev Thomas United States 18 510 0.8× 874 1.5× 483 0.9× 132 0.7× 113 1.2× 58 1.3k
Douglas Bootle Switzerland 13 304 0.5× 582 1.0× 718 1.4× 150 0.8× 96 1.0× 17 1.2k
Axel R. Hanauske Germany 11 490 0.7× 425 0.7× 426 0.8× 132 0.7× 88 0.9× 19 1.0k
Alberto D’Angelo United Kingdom 18 382 0.6× 449 0.8× 348 0.7× 188 1.0× 98 1.0× 59 1000

Countries citing papers authored by Ichiro Kawada

Since Specialization
Citations

This map shows the geographic impact of Ichiro Kawada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ichiro Kawada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ichiro Kawada more than expected).

Fields of papers citing papers by Ichiro Kawada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ichiro Kawada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ichiro Kawada. The network helps show where Ichiro Kawada may publish in the future.

Co-authorship network of co-authors of Ichiro Kawada

This figure shows the co-authorship network connecting the top 25 collaborators of Ichiro Kawada. A scholar is included among the top collaborators of Ichiro Kawada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ichiro Kawada. Ichiro Kawada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yagi, Kazuma, Takanori Asakura, Hideki Terai, et al.. (2023). Clinical features of Japanese patients with gastrointestinal long‐COVID symptoms. JGH Open. 7(12). 998–1002. 2 indexed citations
2.
Horiuchi, Kohei, Shinnosuke Ikemura, Takashi Sato, et al.. (2023). Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis. The Oncologist. 29(1). e108–e117. 12 indexed citations
3.
Shimizu‐Hirota, Ryoko, Masahiro Hashimoto, Ichiro Kawada, et al.. (2021). Unbiased, comprehensive analysis of Japanese health checkup data reveals a protective effect of light to moderate alcohol consumption on lung function. Scientific Reports. 11(1). 15954–15954. 5 indexed citations
4.
Masaki, Katsunori, Shigeharu Ueki, Keiji Tanese, et al.. (2021). Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab. Asia Pacific Allergy. 11(3). e28–e28. 6 indexed citations
5.
Terai, Hideki, Junko Hamamoto, Katsura Emoto, et al.. (2020). SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 19(2). 317–328. 13 indexed citations
6.
Manabe, Tadashi, Hiroyuki Yasuda, Hideki Terai, et al.. (2020). IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Molecular Cancer Research. 18(4). 549–559. 39 indexed citations
7.
Yasuda, Hiroyuki, Keigo Kobayashi, Tetsuo Tani, et al.. (2019). Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics. 18(9). 1593–1601. 3 indexed citations
8.
Hirano, Toshiyuki, Hiroyuki Yasuda, Junko Hamamoto, et al.. (2018). Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 17(4). 740–750. 31 indexed citations
9.
Kobayashi, Keigo, Ichiro Nakachi, Katsuhiko Naoki, et al.. (2018). Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis. Clinical Lung Cancer. 19(3). e349–e358. 45 indexed citations
10.
Nukaga, Shigenari, Hiroyuki Yasuda, Katsuya Tsuchihara, et al.. (2017). Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Research. 77(8). 2078–2089. 131 indexed citations
11.
Hamamoto, Junko, Hiroyuki Yasuda, Makoto Nishino, et al.. (2017). Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. Oncology Letters. 14(3). 3559–3565. 13 indexed citations
12.
Miyawaki, Masayoshi, Hiroyuki Yasuda, Tetsuo Tani, et al.. (2016). Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. Molecular Cancer Research. 15(1). 106–114. 58 indexed citations
13.
Tani, Tetsuo, Hiroyuki Yasuda, Junko Hamamoto, et al.. (2015). Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK -Translocated Lung Cancer Cells. Molecular Cancer Therapeutics. 15(1). 162–171. 54 indexed citations
14.
Asakura, Takanori, Makoto Ishii, Mizuha Haraguchi, et al.. (2015). Dry pleurisy complicating solitary pulmonary nodules caused by Mycobacterium avium: a case report. Journal of Medical Case Reports. 9(1). 238–238. 6 indexed citations
15.
Ikemura, Shinnosuke, Katsuhiko Naoki, Hiroyuki Yasuda, et al.. (2015). A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology. 45(4). 356–361. 6 indexed citations
16.
Kawada, Ichiro, Rifat Hasina, Jeffrey Mueller, et al.. (2013). Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer. Cancer Research. 74(3). 884–895. 52 indexed citations
17.
Salgia, Ravi, et al.. (2013). O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. Journal of Carcinogenesis. 12(1). 20–20. 10 indexed citations
18.
Nwizu, T., Rajani Kanteti, Ichiro Kawada, et al.. (2011). Crizotinib: ALK/Met inhibitor, oncolytic. Drugs of the Future. 36(2). 91–91. 9 indexed citations
19.
Salgia, Ravi, Kenzo Soejima, Essam El‐Hashani, et al.. (2010). MET Mutations And Function In Lung Cancer. Journal of Thoracic Oncology. 5(12). 544. 1 indexed citations
20.
Yasuda, Hiroyuki, Kenzo Soejima, Sohei Nakayama, et al.. (2010). Bronchoscopic Microsampling is a Useful Complementary Diagnostic Tool for Detecting Lung Cancer. Lung Cancer. 72(1). 32–38. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erina Hatashita Breakdown of academic impact, for papers by Ken Uchibori Breakdown of academic impact, for papers by Junko Hamamoto Breakdown of academic impact, for papers by Francesca Casaluce Breakdown of academic impact, for papers by Atsuko Ogino Breakdown of academic impact, for papers by Paola Bordi Breakdown of academic impact, for papers by Sachdev Thomas Breakdown of academic impact, for papers by Douglas Bootle Breakdown of academic impact, for papers by Axel R. Hanauske Breakdown of academic impact, for papers by Alberto D’Angelo
Rankless by CCL
2026